Table 1 Predictors of oncological outcomes using univariable and multivariable Cox proportional hazard models.

From: Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles

Characteristic

Univariable

Multivariable

HR (95% CI)

p-value

HR (95% CI)

p-value

OS Oxford

 Age (mean = 65.1)

1.01 (0.99–1.03)

0.23

—

—

 Male sex

1.45 (0.86–2.45)

0.16

—

—

 Performance status (>1)

2.64 (1.33–5.26)

0.0054

1.42 (0.59–3.43)

0.43

 Baseline BMI

1.01 (0.97–1.05)

0.56

—

—

 Baseline BMI > 25

1.36 (0.72–2.57)

0.34

—

—

 irAE prior to cycle 5

0.30 (0.18–0.51)

9.8 × 10−6

0.28 (0.13–0.58)

0.0006a

 Anti-PD1 treatment

1.72 (0.99–2.97)

0.054

1.23 (0.53–2.89)

0.63

 Prior systemic therapy

1.60 (0.93–2.74)

0.088

1.06 (0.57–1.97)

0.85

 Raised LDH (>255 iu/L)

2.28 (1.18–4.40)

0.014

—

—

 Baseline neutrophil(1 × 106/L)

1.21 (1.12–1.30)

5.4 × 10−7

1.13 (1.01–1.26)

0.029

 Baseline lymphocyte(1 × 106/L)

1.06 (0.71–1.56)

0.79

—

—

 Baseline monocyte(1 × 106/L)

12.0 (6.3–42.5)

8.3 × 10−8

7.00 (2.06–23.79)

0.0018a

 Albumin

0.87 (0.82–0.93)

6 × 10−6

0.93 (0.87–1.01)

0.08

 BRAF mutation

0.78 (0.44–1.41)

0.41

—

—

 Non-cutaneous melanoma

2.8 (1.4–5.6)

0.0035

1.70 (0.73–3.93)

0.22

OS Liverpool

 Age (mean = 64.2)

0.98 (0.97–0.99)

0.005

0.98 (0.97–1.00)

0.013a

 Male sex

1.11 (0.75–1.62)

0.61

—

—

 Baseline BMI

1.01 (0.97– 1.04)

0.76

—

—

 Baseline BMI > 25

1.13 (0.75–1.71)

0.56

—

—

 irAE prior to cycle 5

0.48 (0.33–0.72)

0.00033

0.48 (0.33–0.72)

0.00034a

 Anti-PD1 treatment

1.28 (0.82–1.89)

0.32

—

—

 Prior systemic therapy

2.09 (1.05–4.16)

0.04

1.78 (0.87–3.56)

0.12

 Baseline neutrophil (1 × 106/L)

1.20 (1.10–1.31)

2.2 × 10−5

—

—

 Baseline lymphocyte (1 × 106/L)

0.80 (0.53–1.21)

0.29

—

—

 Low albumin (<36 g/dl)

7.33 (3.50–15.35)

1.3 × 10−7

—

—

  1. Multivariate analysis only performed on variables where 95% or more of values were available for analysis. Albumin threshold as determined for normal range by institution.
  2. aSignificant after FDR correction for multiple testing.
Back to article page